NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-DA-24-026 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-24-197 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to solicit applications for pilot projects to identify new druggable targets for pain within the understudied druggable proteome. Awards will support generation of preliminary data and/or tools around eligible understudied protein(s) listed in this NOFO. This NOFO is intended to jumpstart research on understudied proteins within the context of pain and pain management and provide applicants with sufficient funding to perform basic biochemical and/or biological work to further the characterization of understudied proteins to identify new druggable targets for pain. This NOFO is part of the NIH Helping to End Addiction Long Term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose.
Funding Opportunity PAR-24-174 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages joint applications for the Global Infectious Disease (GID) Research Training programs from U.S. and low- and middle-income country (LMIC) institutions. The application should propose a collaborative training program that will strengthen the capacity of a LMIC institution to conduct infectious disease research. FIC will support research-training programs that focus on major endemic or life-threatening emerging infectious diseases, neglected tropical diseases, infections that frequently occur as co-infections in HIV infected individuals or infections associated with non-communicable disease conditions of public health importance in LMICs. Training related to prevention, treatment or public health approaches to any technical area of basic, epidemiology, clinical, behavioral or social science health research may be supported. Research Training programs should incorporate didactic, mentored research and career development skills components to prepare individuals for careers that will have significant impact on the priority health research needs of LMICs. This Funding Opportunity Announcement (FOA) allows support of [trainees] as the lead investigator of an independent clinical trial; or a separate ancillary clinical trial or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.
Notice NOT-EB-24-007 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-25-130 from the NIH Guide for Grants and Contracts. NIMH seeks applications for pilot research to adapt, optimize, and test empirically supported behavioral interventions that address common sleep problems in adolescents and young adults with or at risk for a mental health disorder. Pilot trials should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach in real world settings, and to conduct a preliminary test of the interventions impact on target mechanisms and sleep and mental health outcomes, and to obtain preliminary data needed as a prerequisite a larger-scale effectiveness trial. An emphasis is placed on studies that address the needs of youth from understudied and underserved populations.
Notice NOT-OD-24-106 from the NIH Guide for Grants and Contracts
Notice NOT-GM-24-030 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-25-035 from the NIH Guide for Grants and Contracts. This NOFO seeks applications from the SUD and MHD research communities that coordinate efforts to characterize the effects of neuromodulation on brain circuits and behaviors relevant to both SUD and MHD. To accomplish this goal, studies would specify inclusion/exclusion criteria to capture variance in both SUD and MHD symptoms. Further, studies would include measures of engagement of circuit-level targets in response to neuromodulation and dimensional measures of cognition and behavior relevant to both SUD and MHD. This research approach uses circuit dynamics to understand neurobehavioral function and to develop ecologically valid and descriptive models of the shared and discrete dysfunction across these conditions.
Notice NOT-EY-24-003 from the NIH Guide for Grants and Contracts
Notice NOT-HD-24-017 from the NIH Guide for Grants and Contracts
Notice NOT-EB-24-008 from the NIH Guide for Grants and Contracts
Notice NOT-HL-24-013 from the NIH Guide for Grants and Contracts
Notice NOT-HL-24-011 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-105 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-095 from the NIH Guide for Grants and Contracts
Notice NOT-CA-24-039 from the NIH Guide for Grants and Contracts
Notice NOT-AT-24-040 from the NIH Guide for Grants and Contracts
Notice NOT-HG-24-031 from the NIH Guide for Grants and Contracts
Notice NOT-HD-24-018 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-24-203 from the NIH Guide for Grants and Contracts. This NOFO will solicit R01 applications that propose studies in animal, cell culture, and/or human tissue models to elucidate the mechanisms by which COVID-19 interacts with and/or modulates AD/ADRD-relevant phenotypes. Either the model itself or the experimental readouts will be required to incorporate AD/ADRD risk factors, pathologies, or relevant comorbidities. To this end, proposals can focus on one or more of the following: - Mechanistic studies that address how COVID-19 impacts CNS pathology and cognitive outcomes when AD/ADRD pathology is already present (for example, in a model of AD/ADRD). - Mechanistic studies that address how COVID-19 accelerates AD/ADRD pathology and cognitive deficits in a prodromal model (early phase, pre-symptomatic). - Mechanistic studies that address how COVID-19 predisposes for AD/ADRD and/or interacts with relevant comorbid conditions and risk factors (cellular mechanisms that could potentially increase the risk for future AD/ADRD).